Holen Sie sich die Stockscreener-App
96.13
5.96%
5.41
Handel nachbörslich:
96.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$90.72
Offen:
$91.2
24-Stunden-Volumen:
2.05M
Relative Volume:
1.65
Marktkapitalisierung:
$11.33B
Einnahmen:
$2.77B
Nettoeinkommen (Verlust:
$286.61M
KGV:
40.91
EPS:
2.35
Netto-Cashflow:
$524.11M
1W Leistung:
+0.24%
1M Leistung:
+1.20%
6M Leistung:
-21.71%
1J Leistung:
-13.15%
1-Tages-Spanne:
$91.17
$96.31
1-Wochen-Bereich:
$89.53
$96.48
52-Wochen-Spanne:
$87.70
$129.50
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Vergleichen Sie RVTY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
96.13 | 11.30B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
What drives Revvity Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
What analysts say about Revvity Inc. stockPowerful profit generation - jammulinksnews.com
Revvity Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
Investors Interested In Revvity, Inc.'s (NYSE:RVTY) Earnings - simplywall.st
Is Revvity Inc. a good long term investmentAccelerated investment success - Autocar Professional
Revvity (RVTY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know - TradingView
How the (RVTY) price action is used to our Advantage - news.stocktradersdaily.com
Earnings Preview: What to Expect From Revvity's Report - MSN
YieldBoost Revvity To 8.9% Using Options - Nasdaq
Ex-Dividend Reminder: Williams Sonoma, Revvity and Zoetis - Nasdaq
Revvity, Inc. Q2 2025 Earnings Preview: Market Expectations and PredictionsNews and Statistics - IndexBox
Revvity Dividend and Company Updates: Key Insights Before Jul 18, 2025 - AInvest
Revvity Inc. Stock Slides 3.0%, Underperforms Market - 富途牛牛
Earnings Preview: What To Expect From Revvity's Report - Barchart.com
Reflecting On Research Tools & Consumables Stocks’ Q1 Earnings: Revvity (NYSE:RVTY) - Yahoo Finance
Revvity (RVTY) Shares Soar 1.98% on Clinical Trial Success - AInvest
Evercore ISI Adjusts Price Target on Revvity to $115 From $116, Maintains Outperform Rating - MarketScreener
(RVTY) Trading Advice - news.stocktradersdaily.com
Revvity to Hold Earnings Call on Monday, July 28, 2025 - Business Wire
Should You Investigate Revvity, Inc. (NYSE:RVTY) At US$101? - simplywall.st
5 Insightful Analyst Questions From Revvity’s Q1 Earnings Call - Yahoo Finance
What 9 Analyst Ratings Have To Say About Revvity - Benzinga
Barclays Keeps Their Buy Rating on Revvity (RVTY) - The Globe and Mail
Is Revvity Stock Underperforming the Dow? - MSN
Is Revvity Stock Underperforming the Dow? A Case for Undervaluation and Growth - AInvest
Leerink Partners Adjusts Price Target on Revvity to $130 From $135, Maintains Outperform Rating - MarketScreener
An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 39% Undervalued - Yahoo Finance
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
How To Trade (RVTY) - news.stocktradersdaily.com
Are Revvity, Inc.'s (NYSE:RVTY) Mixed Financials Driving The Negative Sentiment? - simplywall.st
Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows - SelectScience
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus By Investing.com - Investing.com Canada
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus - Investing.com
Transcript : Revvity, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Revvity To Present At Goldman Sachs Global Healthcare Conference; Webcast At 8:00 AM ET - Nasdaq
Wellington Management Group LLP Has $743,000 Stock Holdings in Revvity, Inc. (NYSE:RVTY) - Defense World
(RVTY) Long Term Investment Analysis - news.stocktradersdaily.com
Revvity gets FDA nod for its automated tuberculosis test - MSN
4 Mass. Rulings You May Have Missed In May - Law360
Revvity (RVTY) Introduces New Mimix Standards for Improved IVD Testing | RVTY Stock News - GuruFocus
New Cancer Testing Standards from Revvity Promise More Accurate Diagnostic Results for Oncology Labs - Stock Titan
Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.06%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):